Here’s the extracted information from the provided visual abstract: SOURCE Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus Study Design: Objective: Participants: Intervention Groups: Primary Outcome: Secondary Outcomes: Conclusion: Citation: This summary captures the key points from the … Read More
SABATO Trial: Oral Antibiotics for Staph Aureus
Here’s the extracted information from the provided visual abstract: SABATO Efficacy and Safety of an Early Oral Switch in Low-risk Staphylococcus aureus Bloodstream Infection Study Design: Objective: Participants: Intervention Groups: Primary Outcome: Secondary Outcome: Conclusion: Citation: This summary captures the … Read More
OPT-BIRISK Trial: Clopidogrel Monotherapy in High Risk ACS
Trial Title: OPT-BIRISKStudy Type: Multicenter, double-blind, randomized trial Objective: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in … Read More
CheckMate 77T Trial: Nivolumab in Lung Cancer
CheckMate 77TPerioperative Nivolumab in Resectable Lung Cancer Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the CheckMate 77T trial, comparing the outcomes of perioperative nivolumab combined with … Read More
SEQUOIA-HCM Trial: Aficamten in HCM
SEQUOIA-HCMAficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the SEQUOIA-HCM trial, comparing the outcomes of aficamten versus placebo in patients with … Read More
STOPDAPT-3 Trial: Prasugrel Monotherapy after PCI
STOPDAPT-3 TrialShort and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcomes: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the STOPDAPT-3 trial, comparing the outcomes … Read More
NOTUS Trial: Dupilumab in COPD
NOTUS TRIAL Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation A double-blind, placebo-controlled, randomized trial Objective:To assess the efficacy and safety of dupilumab in patients with moderate to severe COPD and evidence of type 2 inflammation. 935 … Read More
IRONMAN Trial: IV Iron in HF
IRONMAN Trial Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency A randomized, open-label, blinded-endpoint trial Objective:To evaluate the safety and efficacy of ferric derisomaltose on cardiovascular outcomes among patients with heart failure … Read More
INTERACT4 Trial: Ambulance care for Stroke
INTERACT4 Trial Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke A multicentre, randomized, open-label trial Objective:To determine the effect of prehospital treatment of elevated systolic blood pressure (SBP) in patients with recent onset of symptoms concerning for acute stroke. 2404 Patients … Read More
GZGI Trial: Orforglipron in Obesity
GZGI TRIAL Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Phase 2, randomized, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of orforglipron, an oral non-peptide GLP-1 receptor agonist, for weight reduction in adults with obesity, or … Read More